SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.
ARVO 2024 Presentation Details:
Title: Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up Posterboard Number: B0103 Date & Time: Monday, May 6, 2024 at 8:30 10:15 a.m. PDT Location: Exhibit Hall - Seattle Convention Center Presenter: Dante Joseph Pieramici, M.D., California Retina Consultants
Title: Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing Posterboard Number: B0391 Date & Time: Wednesday, May 8, 2024 at 2:15 4:00 p.m. PDT Location: Exhibit Hall - Seattle Convention Center Presenter: Raj K. Maturi, M.D., Midwest Eye Institute
Additional presentation details and abstracts are available on the ARVO 2024 website here.
About UNITY UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit inage-relatedophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onX andLinkedIn.
Media Contact Inizio Evoke Comms Katherine Smith Katherine.Smith@inizioevoke.com
Investor Contact LifeSci Advisors, LLC Joyce Allaire jallaire@lifesciadvisors.com
See original here:
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - GlobeNewswire
Recommendation and review posted by G. Smith
